NASDAQ:CRVS Corvus Pharmaceuticals Q1 2026 Earnings Results & Report $11.37 +0.02 (+0.18%) Closing price 11/10/2026 04:00 PM EasternExtended Trading$11.36 0.00 (-0.04%) As of 07:34 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Corvus Pharmaceuticals missed analyst earnings expectations in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.15 versus the -$0.14 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 7, 2026TimeAfter Market ClosesConference Call4:00 PM ET Corvus Pharmaceuticals EPS ResultsActual EPS-$0.15Consensus EPS -$0.14Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCorvus Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Corvus Pharmaceuticals Q1 2026 Earnings FAQ Did Corvus Pharmaceuticals beat earnings estimates for Q1 2026? Corvus Pharmaceuticals (NASDAQ:CRVS) reported earnings of -$0.15 per share for Q1 2026, missing the consensus estimate of -$0.14. The report was announced on Thursday, May 7, 2026. Corvus Pharmaceuticals Earnings HeadlinesCorvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real ProductNovember 10 at 7:51 AM | seekingalpha.comCorvus: 'Strong Buy' On Continued Soquelitinib Advancement And HS Data 1st Half 2027November 9 at 6:00 PM | seekingalpha.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 11 at 1:00 AM | Weiss Ratings (Ad)Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference in LondonNovember 9 at 4:05 PM | globenewswire.comCorvus Pharmaceuticals (NASDAQ:CRVS) Stock Dropped to "Strong Sell" by Wall Street ZenNovember 7, 2026 | americanbankingnews.comCorvus Pharmaceuticals, Inc. (CRVS) Q3 2026 Earnings Call TranscriptNovember 6, 2026 | seekingalpha.comSee More Corvus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corvus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corvus Pharmaceuticals and other key companies, straight to your email. Email Address About Corvus PharmaceuticalsCorvus Pharmaceuticals (NASDAQ:CRVS) is a clinical-stage biopharmaceutical company focused on developing medicines that target the immune system to treat cancer and immune-related diseases. The company is based in Burlingame, California, and its work centers on therapies in clinical development rather than marketed products. Its lead candidate, soquelitinib (also known as CPI-818), is an oral inhibitor of interleukin-2-inducible T-cell kinase, or ITK. Corvus is developing the drug for T-cell lymphoma and has also explored its potential in inflammatory and autoimmune conditions, including atopic dermatitis. Corvus was founded in 2014 and is led by co-founder Richard A. Miller, who serves as president and chief executive officer. The company’s development activities are focused on advancing its drug candidates through clinical research.View Corvus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center AmbitionsD-Wave Quantum Has Long-Term Potential, But Is Now the Time to Buy?Archer Aviation's FAA Certificate Is a Milestone, But It Isn't the Final OneRocket Lab's Record Backlog Could Fuel a Rebound, But Neutron Raises the StakesDraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
